154 related articles for article (PubMed ID: 34214002)
1. A patent review of MALT1 inhibitors (2013-present).
Hamp I; O'Neill TJ; Plettenburg O; Krappmann D
Expert Opin Ther Pat; 2021 Dec; 31(12):1079-1096. PubMed ID: 34214002
[TBL] [Abstract][Full Text] [Related]
2. A MALT1 inhibitor suppresses human myeloid DC, effector T-cell and B-cell responses and retains Th1/regulatory T-cell homeostasis.
Dumont C; Sivars U; Andreasson T; Odqvist L; Mattsson J; DeMicco A; Pardali K; Johansson G; Yrlid L; Cox RJ; Seeliger F; Larsson M; Gehrmann U; Davis AM; Vaarala O
PLoS One; 2020; 15(9):e0222548. PubMed ID: 32870913
[TBL] [Abstract][Full Text] [Related]
3. Peptide-based covalent inhibitors of MALT1 paracaspase.
Hatcher JM; Du G; Fontán L; Us I; Qiao Q; Chennamadhavuni S; Shao J; Wu H; Melnick A; Gray NS; Scott DA
Bioorg Med Chem Lett; 2019 Jun; 29(11):1336-1339. PubMed ID: 30954428
[TBL] [Abstract][Full Text] [Related]
4. MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner.
Demeyer A; Skordos I; Driege Y; Kreike M; Hochepied T; Baens M; Staal J; Beyaert R
Front Immunol; 2019; 10():1898. PubMed ID: 31474984
[TBL] [Abstract][Full Text] [Related]
5. Function and targeting of MALT1 paracaspase in cancer.
O'Neill TJ; Tofaute MJ; Krappmann D
Cancer Treat Rev; 2023 Jun; 117():102568. PubMed ID: 37126937
[TBL] [Abstract][Full Text] [Related]
6. Combining precision oncology and immunotherapy by targeting the MALT1 protease.
Mempel TR; Krappmann D
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36270731
[TBL] [Abstract][Full Text] [Related]
7. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.
Fontán L; Qiao Q; Hatcher JM; Casalena G; Us I; Teater M; Durant M; Du G; Xia M; Bilchuk N; Chennamadhavuni S; Palladino G; Inghirami G; Philippar U; Wu H; Scott DA; Gray NS; Melnick A
J Clin Invest; 2018 Oct; 128(10):4397-4412. PubMed ID: 30024860
[TBL] [Abstract][Full Text] [Related]
8. Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad?
Demeyer A; Staal J; Beyaert R
Trends Mol Med; 2016 Feb; 22(2):135-150. PubMed ID: 26787500
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Inhibition of MALT1 Ameliorates Autoimmune Pathogenesis and Can Be Uncoupled From Effects on Regulatory T-Cells.
Biswas S; Chalishazar A; Helou Y; DiSpirito J; DeChristopher B; Chatterjee D; Merselis L; Vincent B; Monroe JG; Rabah D; Long AJ
Front Immunol; 2022; 13():875320. PubMed ID: 35615349
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology.
Martin K; Junker U; Tritto E; Sutter E; Rubic-Schneider T; Morgan H; Niwa S; Li J; Schlapbach A; Walker D; Bigaud M; Beerli C; Littlewood-Evans A; Rudolph B; Laisney M; Ledieu D; Beltz K; Quancard J; Bornancin F; Zamurovic Ribrioux N; Calzascia T
Front Immunol; 2020; 11():745. PubMed ID: 32425939
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease.
Asaba KN; Adachi Y; Tokumaru K; Watanabe A; Goto Y; Aoki T
Bioorg Med Chem Lett; 2021 Jun; 41():127996. PubMed ID: 33775836
[TBL] [Abstract][Full Text] [Related]
12. Chemical Probes for Profiling of MALT1 Protease Activity.
Verhelst SHL; Prothiwa M
Chembiochem; 2023 Nov; 24(21):e202300444. PubMed ID: 37607867
[TBL] [Abstract][Full Text] [Related]
13. Discovery and optimization of cyclohexane-1,4-diamines as allosteric MALT1 inhibitors.
Schiesser S; Hajek P; Pople HE; Käck H; Öster L; Cox RJ
Eur J Med Chem; 2022 Jan; 227():113925. PubMed ID: 34742013
[TBL] [Abstract][Full Text] [Related]
14. Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease.
Lu T; Connolly PJ; Philippar U; Sun W; Cummings MD; Barbay K; Gys L; Van Nuffel L; Austin N; Bekkers M; Shen F; Cai A; Attar R; Meerpoel L; Edwards J
Bioorg Med Chem Lett; 2019 Dec; 29(23):126743. PubMed ID: 31678006
[TBL] [Abstract][Full Text] [Related]
15. Normal lymphocyte homeostasis and function in MALT1 protease-resistant HOIL-1 knock-in mice.
Skordos I; Driege Y; Haegman M; Kreike M; Staal J; Demeyer A; Beyaert R
FEBS J; 2023 Apr; 290(8):2032-2048. PubMed ID: 36479846
[TBL] [Abstract][Full Text] [Related]
16. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.
Quancard J; Klein T; Fung SY; Renatus M; Hughes N; Israël L; Priatel JJ; Kang S; Blank MA; Viner RI; Blank J; Schlapbach A; Erbel P; Kizhakkedathu J; Villard F; Hersperger R; Turvey SE; Eder J; Bornancin F; Overall CM
Nat Chem Biol; 2019 Mar; 15(3):304-313. PubMed ID: 30692685
[TBL] [Abstract][Full Text] [Related]
17. Malt1 Protease Deficiency in Mice Disrupts Immune Homeostasis at Environmental Barriers and Drives Systemic T Cell-Mediated Autoimmunity.
Martin K; Touil R; Kolb Y; Cvijetic G; Murakami K; Israel L; Duraes F; Buffet D; Glück A; Niwa S; Bigaud M; Junt T; Zamurovic N; Smith P; McCoy KD; Ohashi PS; Bornancin F; Calzascia T
J Immunol; 2019 Dec; 203(11):2791-2806. PubMed ID: 31659015
[TBL] [Abstract][Full Text] [Related]
18. Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice.
Baens M; Stirparo R; Lampi Y; Verbeke D; Vandepoel R; Cools J; Marynen P; de Bock CE; Bornschein S
Eur J Immunol; 2018 Oct; 48(10):1728-1738. PubMed ID: 30025160
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Potential of Targeting Malt1-Dependent TCR Downstream Signaling to Promote the Survival of MHC-Mismatched Allografts.
Govender L; Mikulic J; Wyss JC; Gaide O; Thome M; Golshayan D
Front Immunol; 2020; 11():576651. PubMed ID: 33042160
[TBL] [Abstract][Full Text] [Related]
20. MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-κB and NLRP3 inflammasome activation.
Liu W; Guo W; Hang N; Yang Y; Wu X; Shen Y; Cao J; Sun Y; Xu Q
Oncotarget; 2016 May; 7(21):30536-49. PubMed ID: 27105502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
